Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evaluation in man of bumetanide, a new diuretic agent

  • 33 Accesses

  • 16 Citations

Summary

Bumetanide, a new diuretic, has been studied in ten healthy volunteers, who received single oral doses of 0.125 to 1.50 mg. It was potent and had, a rapid action; the maximum effect occurred within 60 to 90 min and lasted for 5 to 6 h. Within 60–90 min of a 1 mg dose the urine volume increased from 1 to about 10 ml/min and sodium excretion from about 100 µEq/min to about 1000 µEq/min. There was only a slight increase in potassium excretion. The mean total urinary volume during the first six hours after 1 mg of bumetanide was approximately 1500 ml. The increase of diuresis and saluresis after 0.125 mg was slight. In the dosage range of 0.125 to 1.0 mg there was a linear relationship between dose and increase in urinary volume and sodium excretion. Increasing the dose from 1.0 to 1.5 mg did not produce a correspondingly larger diuresis. The optimal range of doses of bumetanide appears to lie between 0.25 to 1.00 mg, according to the present results obtained in ten healthy volunteers.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Asbury, M.J., Gatenby, P.B.B., O'Sullivan, S., Bourke, E.: Bumetanide: Potent new “loop” diuretic. Brit. med. J.1972 I, 211

  2. 2.

    Baer, J.E., Beyer, K.H.: Renal pharmacology. Ann. Rev. Pharmacol.6, 261 (1966)

  3. 3.

    Bourke, E., Counihan, T.B., Keelan, P., Ryan, M.: Clinical trial of a new diuretic: ethacrynic acid. J. Irish med. Ass.56, 1 (1965)

  4. 4.

    Brun, C.: Klorbestemmelse. Nord. Med.42, 1774 (1949)

  5. 5.

    Catt, K.J., Cran, E., Zimmet, P.Z., Best, J.B., Cain, M.D., Coghlan, J.P.: Angiotensin II blood-levels in human hypertension. Lancet1971 II, 459

  6. 6.

    Feit, P.W.: Aminobenzoic acid diuretics. J. med. pharm. Chem.14, 432 (1971)

  7. 7.

    Giese, J., Aurell, M., Munck, O.: Pheripheral and renal venous plasma renin concentration in hypertensive patients with unilateral renal or renovascular disease. Scand. J. Urol. Nephrol. 6 Suppl.15, 39 (1972)

  8. 8.

    Karlander, S.-G., Henning, E.R., Lundvall, O.: Renal effects of bumetanide, a new saluretic agent. Europ. J. clin. Pharmacol.6, 220 (1973)

  9. 9.

    Laragh, J.H., Cannon, P.J., Stason, W.B., Heineman, H.O.: Physiologic and clinical observations on furosemide and ethacrynic acid. Ann. N.Y. Acad. Sci.139, 453 (1966)

  10. 10

    Rector, F.C. jr. Clapp, J.R.: Evidence for active chloride reabsorption in the distal renal tubule of the rat. J. Clin. Invest.41, 101 (1962)

  11. 11.

    Rosenthal, J., Boucher, R., Nowacynski, W., Genest, J.: Acute changes in plasma volume, renin activity, and free aldosterone levels on healthy subjects following furosemide administration. Canad. J. Physiol. Pharmacol.46, 385 (1968)

  12. 12.

    Stason, W.B., Cannon, P.J., Heinemann, H.O., Laragh, J.H.: Furosemide, a clinical evaluation of its diuretic action. Circulation34, 910 (1966)

  13. 13.

    Ostergaard, E.H., Magnussen, M.P., Kaergaard Nielsen, Chr., Eilertsen, Eva, Frey, H.-H.: Pharmacological properties of bumetanide, a new potent diuretic. Arzneimittel-Forsch.22, 66 (1972)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Henning, R., Lundvall, O. Evaluation in man of bumetanide, a new diuretic agent. Eur J Clin Pharmacol 6, 224–227 (1973). https://doi.org/10.1007/BF00644736

Download citation

Key words

  • Bumetanide
  • diuretic
  • human trials